Skip to main content

Precise Bio

ApplicationGreensboro, NC, USAFounded 2015· One of 381 Application companies tracked by AMPulse

Develops a 4D biofabrication platform for transplantable tissues and organs, combining cell expansion, biomaterials, and printing technology, with initial focus on corneal grafts for ophthalmology.

CEO / Founder
Aryeh Batt
Team Size
51-200
Stage
Early Stage
Total Funding
$27.5M
Latest Round
Series C
Key Investors
ZEISS; Aurum Ventures

Technology & Products

Key Products

4D biofabrication platform; Bio-printed corneal grafts (DSEK/DMEK/PK); Cardiac tissue patch for post-myocardial infarction; Ophthalmic pipeline including retinal patches and vision-correction lenticules

Technological Advantage

Verified advantage: First-in-animal corneal graft transplants demonstrated; claimed advantage: Platform designed for scalable manufacturing under GMP conditions. Defensible through proprietary processes and partnerships.

Differentiation

Value Proposition

Provides scalable, reproducible bio-fabricated tissues to address donor shortages, enabling on-demand production of clinical-grade human tissues like corneas with potential to reduce transplant wait times and improve outcomes.

How They Differentiate

Focus on 4D biofabrication for transplantable tissues with initial ophthalmology applications, offering higher reproducibility and scalability compared to standard 3D bioprinting; has achieved first animal corneal transplants and strategic partnership with Carl Zeiss Meditec.

Market & Competition

Target Customers

Hospitals, eye banks, clinicians in ophthalmology and regenerative medicine

Industry Verticals

Healthcare; Biotechnology; Regenerative Medicine

Competitors

Cellink; Aspect Biosystems; Organovo

Growth & Milestones

Growth Metrics

Raised $15.5M in funding; team size approximately 11-50 employees; progressing toward first-in-human trials for bioprinted corneas.

Major Milestones

First animal corneal graft transplant; First human corneal implant (Oct 2025); Additional patients treated (Feb 2026); Launch of ophthalmology business unit; Strategic partnership with Carl Zeiss Meditec

Notable Customers

Carl Zeiss Meditec

https://www.precise-bio.com

Why this company matters

Precise Bio develops a 4D biofabrication platform for transplantable tissues and organs, combining cell expansion, biomaterials, and bioprinting. The company's initial focus is on corneal grafts for ophthalmology, aiming to address donor shortages by enabling on-demand production of clinical-grade human tissues with high reproducibility.

The core technology integrates cell biology, biomaterials, and material extrusion bioprinting to produce tissues that mature after printing. This 4D approach allows complex tissue generation with transferable learnings across tissue types. The platform is designed for scalable manufacturing under GMP conditions, with a pipeline including bio-printed corneal grafts for DSEK, DMEK, and PK procedures, as well as cardiac tissue patches and retinal patches.

Target customers include hospitals, eye banks, and clinicians in ophthalmology and regenerative medicine. Precise Bio has a strategic partnership with Carl Zeiss Meditec for co-development and funding of corneal tissues, and has achieved first-in-animal corneal graft transplants. The company is progressing toward first-in-human trials for bioprinted corneas.

Precise Bio differentiates from competitors like Cellink, Aspect Biosystems, and Organovo through its 4D biofabrication approach and initial ophthalmology applications. The company has raised $27.5M from investors including ZEISS and Aurum Ventures. Key open questions include whether the platform can achieve the scalability and regulatory approval needed to move from animal studies to commercial clinical use.